Greenwood In The “Wolves’ Den”: BIO CEO Visits GPhA
This article was originally published in The Pink Sheet Daily
Executive Summary
His address to the generic association’s annual meeting is cordial, but “consensus is difficult,” on follow-on biologics, Greenwood says. “We just may have an amendment battle and count the votes.”
You may also be interested in...
Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says
GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.
Drug Safety Problems Show Potential For Follow-On Biologics, Jaeger Says
GPhA President Jaeger argues that improved analytics developed in the wake of the heparin problems suggest that non-clinical verification of follow-on products is possible.
Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest
Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.